denosumab Prolia
Selected indexed studies
- The Clinical Effectiveness of Denosumab (Prolia®) for the Treatment of Osteoporosis in Postmenopausal Women, Compared to Bisphosphonates, Selective Estrogen Receptor Modulators (SERM), and Placebo: A Systematic Review and Network Meta-Analysis. (Calcif Tissue Int, 2023) [PMID:37016189]
- Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. (Lancet, 2015) [PMID:26144908]
- Denosumab discontinuation in the clinic: implications of rebound bone turnover and emerging strategies to prevent bone loss and fractures. (J Bone Miner Res, 2025) [PMID:40057981]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Prevention and Management of Denosumab Discontinuation Rebound Fractures. (2024) pubmed
- Denosumab discontinuation in the clinic: implications of rebound bone turnover and emerging strategies to prevent bone loss and fractures. (2025) pubmed
- Stopping Denosumab. (2019) pubmed
- Denosumab for osteoporosis treatment: when, how, for whom, and for how long. A pragmatical approach. (2025) pubmed
- Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. (2015) pubmed
- Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS. (2017) pubmed
- The Clinical Effectiveness of Denosumab (Prolia®) for the Treatment of Osteoporosis in Postmenopausal Women, Compared to Bisphosphonates, Selective Estrogen Receptor Modulators (SERM), and Placebo: A Systematic Review and Network Meta-Analysis. (2023) pubmed
- The clinical effectiveness of denosumab (Prolia®) in patients with hormone-sensitive cancer receiving endocrine therapy, compared to bisphosphonates, selective estrogen receptor modulators (SERM), and placebo: a systematic review and network meta-analysis. (2023) pubmed
- Equivalence trial of proposed denosumab biosimilar GP2411 and reference denosumab in postmenopausal osteoporosis: the ROSALIA study. (2024) pubmed
- Denosumab (prolia) for treatment of postmenopausal osteoporosis. (2012) pubmed